The efficacy and safety of onartuzumab in patients with solid cancers: A meta-analysis of randomized trials
Conclusion: This meta-analysis indicates that the addition of onartuzumab to the standard treatments had no definite survival benefit with increased severe toxicities in patients with solid cancer.
Source: Indian Journal of Cancer - Category: Cancer & Oncology Authors: Bum Jun Kim Dalyong Kim Jung Han Kim Hyeong Su Kim Hyun Joo Jang Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Databases & Libraries | India Health | Lung Cancer | Non-Small Cell Lung Cancer | Study | Thrombocytopenia | Toxicology